June 21 Preclinical Quick Takes: AnaptysBio targets PD-1 for immune disease; plus Forty Seven, Homology and moreBy BioCentury Staff

AnaptysBio agonizes PD-1 for inflammatory disease
AnaptysBio Inc. (NASDAQ:ANAB) presented what CEO Hamza Suria called “the first data from anyone on a PD-1 agonist mAb” at the 2019 Federation of Clinical Immunology Societies (FOCiS) meeting Wednesday, showing its wholly owned PD-1 agonist mAb ANB030 inhibited tetanus toxoid recall

Read the full 477 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE